Invasive Fungal Infections in the ICU

Journal of Intensive Care Medicine

Volumn 25, Issue 2, 2010, Pages 78-92

  Shoham, Shmuel ^a   Marwaha, Shilpa ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

Aspergillosis; Candidiasis; Fungus; Intensive; Sepsis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLODEXTRIN; CYCLOSPORIN; FLUCONAZOLE; HYDROCORTISONE; MICAFUNGIN; PARACETAMOL; PETHIDINE; POLYENE; TACROLIMUS; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; AREA UNDER THE CURVE; ARTHRALGIA; ASPERGILLOSIS; AUDITORY HALLUCINATION; BLOOD CULTURE; BLOOD SMEAR; CANDIDA MENINGITIS; CANDIDEMIA; CHILL; CRITICALLY ILL PATIENT; CRYPTOCOCCOSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXFOLIATIVE DERMATITIS; FLANK PAIN; FUNGAL COLONIZATION; FUNGUS CULTURE; FUNGUS TRANSMISSION; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; HISTOPLASMOSIS; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; INFECTION PREVENTION; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; LENGTH OF STAY; LIVER FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; LUNG LAVAGE; MORBIDITY; MUCORMYCOSIS; MULTILOCUS SEQUENCE TYPING; MYALGIA; NAUSEA; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; REVIEW; RIGOR; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SMEAR; THORAX PAIN; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING;

ANTIFUNGAL AGENTS; CROSS INFECTION; HOST-PATHOGEN INTERACTIONS; HUMANS; INTENSIVE CARE UNITS; MYCOSES; RISK FACTORS;

EID: 77950293002     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066609355262     Document Type: Review

References (215)

1. Meersseman W., Vandecasteele SJ, Wilmer A., Verbeken E., Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004 ; 170 (6). 621-625.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999 ; 29 (2). 239-244.
3. Martin GS, Mannino DM, Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 ; 348 (16). 1546-1554.
4. Jarvis WR Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 1995 ; 20 (6). 1526-1530.
5. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004 ; 42 (4). 1519-1527.
6. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995 ; 274 (8). 639-644.
7. Rangel-Frausto MS, Wiblin T., Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999 ; 29 (2). 253-258.
8. Cliff PR, Sandoe JA, Heritage J., Barton RC Use of multilocus sequence typing for the investigation of colonisation by Candida albicans in intensive care unit patients. J Hosp Infect. 2008 ; 69 (1). 24-32.
9. Petri MG, Konig J., Moecke HP, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med. 1997 ; 23 (3). 317-325.
10. Charles PE, Dalle F., Aube H., et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 2005 ; 31 (3). 393-400.
11. Bartholomew GA, Rodu B., Bell DS Oral candidiasis in patients with diabetes mellitus: a thorough analysis. Diabetes Care. 1987 ; 10 (5). 607-612.
12. Bendel CM, Wiesner SM, Garni RM, Cebelinski E., Wells CL Cecal colonization and systemic spread of Candida albicans in mice treated with antibiotics and dexamethasone. Pediatr Res. 2002 ; 51 (3). 290-295.
13. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect. 2006 ; 63 (3). 246-254.
14. Christiaens G., Hayette MP, Jacquemin D., Melin P., Mutsers J., De Mol P. An outbreak of Absidia corymbifera infection associated with bandage contamination in a burns unit. J Hosp Infect. 2005 ; 61 (1). 88.
15. Cahill BC, Hibbs JR, Savik K., et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997 ; 112 (5). 1160-1164.
16. Garnacho-Montero J., Amaya-Villar R., Ortiz-Leyba C., et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005 ; 9 (3). R191 - R199.
17. Pihet M., Carrere J., Cimon B., et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med Mycol. 2009 ; 47 (4). 387-397.
18. Immune Response to Fungal Infections. Toronton, ON: Mechanisms in Medicine ; 2008.
19. Schaffner A., Douglas H., Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest. 1982 ; 69 (3). 617-631.
20. Spellberg B. Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog. 2008 ; 4 (2). e38.
21. Nucci M., Anaissie E. Revisiting the source of candidemia: skin or gut ? Clin Infect Dis. 2001 ; 33 (12). 1959-1967.
22. Koh AY, Kohler JR, Coggshall KT, Van Rooijen N., Pier GB Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog. 2008 ; 4 (2). e35.
23. Pappo I., Polacheck I., Zmora O., Feigin E., Freund HR Altered gut barrier function to Candida during parenteral nutrition. Nutrition. 1994 ; 10 (2). 151-154.
24. Pyrgos V., Ratanavanich K., Donegan N., Veis J., Walsh TJ, Shoham S. Candida bloodstream infections in hemodialysis recipients. Med Mycol. 2008: 1-5 ; [Epub ahead of print].
25. Shoham S., Levitz SM The immune response to fungal infections. Br J Haematol. 2005 ; 129 (5). 569-582.
26. Mowat A., Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971 ; 284 (12). 621-627.
27. Subbaiah PV, Bagdade JD Host defense mellitus: defective membrane synthesis during phagocytosis. Horm Metab Res. 1982 ; 14 (9). 445-448.
28. Bagdade JD, Stewart M., Walters E. Impaired granulocyte adherence. A reversible defect in host defense in patients with poorly controlled diabetes. Diabetes. 1978 ; 27 (6). 677-681.
29. Alexiewicz JM, Kumar D., Smogorzewski M., Klin M., Massry SG Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med. 1995 ; 123 (12). 919-924.
30. Shoham S., Han G., Granek T., Walsh TJ, Magee M. An association between blood glucose levels and development of Candidemia in hospitalized patients. Endocrine Practice. 2009 ; 15 (2). 111-115.
31. Engelich G., Wright DG, Hartshorn KL Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin Infect Dis. 2001 ; 33 (12). 2040-2048.
32. Ruiz P., Gomez F., Schreiber AD Impaired function of macrophage Fc gamma receptors in end-stage renal disease. N Engl J Med. 1990 ; 322 (11). 717-722.
33. Jorstad S., Smeby LC, Wideroe TE, Berg KJ Transport of uremic toxins through conventional hemodialysis membranes. Clin Nephrol. 1979 ; 12 (4). 168-173.
34. Gibbons RA, Martinez OM, Garovoy MR Altered monocyte function in uremia. Clin Immunol Immunopathol. 1990 ; 56 (1). 66-80.
35. Jorstad S., Viken KE Inhibitory effects of plasma from uraemic patients on human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand [C]. 1977 ; 85 (3). 169-177.
36. Bellocchio S., Montagnoli C., Bozza S., et al. The contribution of the toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol. 2004 ; 172 (5). 3059-3069.
37. Mezger M., Kneitz S., Wozniok I., Kurzai O., Einsele H., Loeffler J. Proinflammatory response of immature human dendritic cells is mediated by dectin-1 after exposure to Aspergillus fumigatus germ tubes. J Infect Dis. 2008 ; 197 (6). 924-931.
38. Netea MG, Gow NA, Munro CA, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest. 2006 ; 116 (6). 1642-1650.
39. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008 ; 359 (17). 1766-1777.
40. Diamond RD, Krzesicki R., Epstein B., Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol. 1978 ; 91 (2). 313-328.
41. Tang YQ, Yeaman MR, Selsted ME Antimicrobial peptides from human platelets. Infect Immun. 2002 ; 70 (12). 6524-6533.
42. Yeaman MR, Soldan SS, Ghannoum MA, Edwards JE Jr, Filler SG, Bayer AS Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis. Infect Immun. 1996 ; 64 (4). 1379-1384.
43. Cenci E., Mencacci A., Fe d'Ostiani C., et al. Cytokineand T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis. 1998 ; 178 (6). 1750-1760.
44. Cenci E., Perito S., Enssle KH, et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun. 1997 ; 65 (2). 564-570.
45. Montagnoli C., Bacci A., Bozza S., et al. B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to. Candida albicans. J Immunol. 2002 ; 169 (11). 6298-6308.
46. Bagdade JD, Walters E. Impaired granulocyte adherence in mildly diabetic patients: effects of tolazamide treatment. Diabetes. 1980 ; 29 (4). 309-311.
47. Chen Z., O'Shea JJ Th17 cells: a new fate for differentiating helper T cells. Immunol Res. 2008 ; 41 (2). 87-102.
48. De Luca A., Montagnoli C., Zelante T., et al. Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J Immunol. 2007 ; 179 (9). 5999-6008.
49. Zelante T., De Luca A., Bonifazi P., et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007 ; 37 (10). 2695-2706.
50. Shoham S., Groll AH, Walsh TJ Antifungal agents. In: Cohen J, Powderly W, eds. Infectious Diseases. 3 rd ed. Mosby ; in press.
51. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003 ; 36 (10). 1221-1228.
52. Sobel JD, Revankar SG Echinocandins-first-choice or first-line therapy for invasive candidiasis ? N Engl J Med. 2007 ; 356 (24). 2525-2526.
53. Louie A., Drusano GL, Banerjee P., et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 1998 ; 42 (5). 1105-1109.
54. Baddley JW, Patel M., Bhavnani SM, Moser SA, Andes DR Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008 ; 52 (9). 3022-3028.
55. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against. Candida albicans. Antimicrob Agents Chemother. 1997 ; 41 (6). 1392-1395.
56. Brammer KW, Farrow PR, Faulkner JK Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990 ; 12 (suppl 3). S318 - S326.
57. Barquist ES, Gomez-Fein E., Block EF, Collin G., Alzamel H., Martinez O. Bioavailability of oral fluconazole in critically ill abdominal trauma patients with and without abdominal wall closure: a randomized crossover clinical trial. J Trauma. 2007 ; 63 (1). 159-163.
58. Pappas PG, Kauffman CA, Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 ; 48 (5). 503-535.
59. Lee JW, Seibel NL, Amantea M., Whitcomb P., Pizzo PA, Walsh TJ Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr. 1992 ; 120 (6). 987-993.
60. Saxen H., Hoppu K., Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993 ; 54 (3). 269-277.
61. Wade KC, Wu D., Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008 ; 52 (11). 4043-4049.
62. Como JA, Dismukes WE Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994 ; 330 (4). 263-272.
63. Esch JJ, Kantoch MJ Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Pediatr Cardiol. 2008 ; 29 (1). 210-213.
64. Groll AH, Piscitelli SC, Walsh TJ Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, putative targets for antifungal drug development. Adv Pharmacol. 1998 ; 44: 343-500.
65. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997 ; 24 (2). 235-247.
66. Reller ME, Mallonee AB, Kwiatkowski NP, Merz WG Use of peptide nucleic acid-fluorescence in situ hybridization for definitive, rapid identification of five common Candida species. J Clin Microbiol. 2007 ; 45 (11). 3802-3803.
67. Meyer E., Schwab F., Gastmeier P., Ruden H., Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother. 2007 ; 60 (3). 619-624.
68. Playford EG, Eggimann P., Calandra T. Antifungals in the ICU. Curr Opin Infect Dis. 2008 ; 21 (6). 610-619.
69. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004 ; 38 (2). 161-189.
70. Eggimann P., Francioli P., Bille J., et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999 ; 27 (6). 1066-1072.
71. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001 ; 233 (4). 542-548.
72. Cruciani M., de Lalla F., Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med. 2005 ; 31 (11). 1479-1487.
73. Klepser ME, Malone D., Lewis RE, Ernst EJ, Pfaller MA Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother. 2000 ; 44 (7). 1917-1920.
74. Simitsopoulou M., Roilides E., Paliogianni F., et al. Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob Agents Chemother. 2008 ; 52 (9). 3301-3306.
75. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008 ; 46 (2). 201-211.
76. Walsh TJ, Karlsson MO, Driscoll T., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004 ; 48 (6). 2166-2172.
77. Abel S., Allan R., Gandelman K., Tomaszewski K., Webb DJ, Wood ND Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig. 2008 ; 28 (7). 409-420.
78. Alvarez-Lerma F., Allepuz-Palau A., Garcia MP, et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother. 2008 ; 20 (1). 93-100.
79. Johnson LB, Kauffman CA Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003 ; 36 (5). 630-637.
80. Zonios DI, Gea-Banacloche J., Childs R., Bennett JE Hallucinations during voriconazole therapy. Clin Infect Dis. 2008 ; 47 (1). e7 - e10.
81. Herbrecht R., Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 ; 347 (6). 408-415.
82. Kullberg BJ, Sobel JD, Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005 ; 366 (9495). 1435-1442.
83. Husain S., Paterson DL, Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006 ; 6 (12). 3008-3016.
84. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis. 2006 ; 55 (3). 209-212.
85. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M., Marr KA Clinical significance of azole antifungal drug cross-resistance in. Candida glabrata. J Clin Microbiol. 2006 ; 44 (5). 1740-1743.
86. Myoken Y., Kyo T., Sugata T., Murayama SY, Mikami Y. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. Haematologica. 2006 ; 91 (2). 287-288.
87. Magill SS, Shields C., Sears CL, Choti M., Merz WG Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol. 2006 ; 44 (2). 529-535.
88. Walsh TJ, Teppler H., Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004 ; 351 (14). 1391-1402.
89. Maertens J., Raad I., Petrikkos G., et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant (I) to other antifungal agents: an analysis of 90 patients. Abstract M-868. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology ; 2002: 388.
90. Caillot D., Thiebaut A., Herbrecht R., et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007 ; 110 (12). 2740-2746.
91. Cesaro S., Giacchino M., Locatelli F., et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis. 2007 ; 7: 28.
92. Marr KA, Boeckh M., Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004 ; 39 (6). 797-802.
93. Reed C., Bryant R., Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008 ; 47 (3). 364-371.
94. Georgopapadakou NH Update on antifungals targeted to the cell wall: Focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs. 2001 ; 10 (2). 269-280.
95. Kurtz MB, Douglas CM Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol. 1997 ; 35 (2). 79-86.
96. Ernst EJ, Klepser ME, Pfaller MA Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000 ; 44 (4). 1108-1111.
97. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis. 1999 ; 33 (2). 75-80.
98. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L., et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008 ; 46 (8). 2620-2629.
99. Hohl TM, Feldmesser M., Perlin DS, Pamer EG Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis. 2008 ; 198 (2). 176-185.
100. Lamaris GA, Lewis RE, Chamilos G., et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008 ; 198 (2). 186-192.
101. Balani SK, Xu X., Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos. 2000 ; 28 (11). 1274-1278.
102. Walsh T., Adamson P., Seibel N., et al. Pharmacokinetics (PK) of Caspofungin (CAS) in Pediatric Patients. Abstract M-896. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology ; 2002: 395.
103. Zaoutis TE, Argon J., Chu J., Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005 ; 41 (9). 1232-1239.
104. Benjamin DK Jr, Driscoll T., Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006 ; 50 (2). 632-638.
105. Sobel JD Changing epidemiology of invasive candidiasis in intensive care units-much ado about nothing ? Crit Care Med. 2008 ; 36 (7). 2188-2189.
106. Reboli AC, Rotstein C., Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007 ; 356 (24). 2472-2482.
107. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007 ; 45 (7). 883-893.
108. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002 ; 347 (25). 2020-2029.
109. Gagos M., Koper R., Gruszecki WI Spectrophotometric analysis of organisation of dipalmitoylphosphatidylcholine bilayers containing the polyene antibiotic amphotericin B. Biochim Biophys Acta. 2001 ; 1511 (1). 90-98.
110. Milhaud J., Ponsinet V., Takashi M., Michels B. Interactions of the drug amphotericin B with phospholipid membranes containing or not ergosterol: new insight into the role of ergosterol. Biochim Biophys Acta. 2002 ; 1558 (2). 95-108.
111. Groll AH, Piscitelli SC, Walsh TJ Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy. 2001 ; 21 (8 pt 2). 133S - 148S.
112. Turnidge JD, Gudmundsson S., Vogelman B., Craig WA The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother. 1994 ; 34 (1). 83-92.
113. Andes D., Stamsted T., Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001 ; 45 (3). 922-926.
114. Dotis J., Simitsopoulou M., Dalakiouridou M., et al. Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus. J Antimicrob Chemother. 2008 ; 61 (4). 810-817.
115. Dotis J., Simitsopoulou M., Dalakiouridou M., et al. Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus. Antimicrob Agents Chemother. 2006 ; 50 (3). 868-873.
116. Benson JM, Nahata MC Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother. 1989 ; 33 (11). 1989-1993.
117. Walsh TJ, Finberg RW, Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999 ; 340 (10). 764-771.
118. Harbarth S., Pestotnik SL, Lloyd JF, Burke JP, Samore MH The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med. 2001 ; 111 (7). 528-534.
119. Johnson MD, Drew RH, Perfect JR Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy. 1998 ; 18 (5). 1053-1061.
120. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 ; 46 (3). 327-360.
121. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000 ; 30 (4). 710-718.
122. Hughes WT, Armstrong D., Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 ; 34 (6). 730-751.
123. Ullmann AJ, Sanz MA, Tramarin A., et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis. 2006 ; 43 (4). e29 - e38.
124. Bougnoux ME, Kac G., Aegerter P., d'Enfert C., Fagon JY Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008 ; 34 (2). 292-299.
125. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care. 2007 ; 22 (3). 237-244.
126. Gudlaugsson O., Gillespie S., Lee K., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003 ; 37 (9). 1172-1177.
127. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998 ; 27 (4). 781-788.
128. Zaoutis TE, Heydon K., Localio R., Walsh TJ, Feudtner C. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007 ; 44 (9). 1187-1193.
129. Dupont H., Bourichon A., Paugam-Burtz C., Mantz J., Desmonts JM Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med. 2003 ; 31 (3). 752-757.
130. Ang BS, Telenti A., King B., Steckelberg JM, Wilson WR Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis. 1993 ; 17 (4). 662-666.
131. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000 ; 30 (1). 14-18.
132. Sobel JD, Kauffman CA, McKinsey D., et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis. 2000 ; 30 (1). 19-24.
133. Wisplinghoff H., Bischoff T., Tallent SM, Seifert H., Wenzel RP, Edmond MB Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004 ; 39 (3). 309-317.
134. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001 ; 33 (2). 177-186.
135. Eggimann P., Garbino J., Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003 ; 3 (11). 685-702.
136. Voss A., le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF Candidemia in intensive care unit patients: risk factors for mortality. Infection. 1997 ; 25 (1). 8-11.
137. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002 ; 35 (5). 627-630.
138. Luzzati R., Allegranzi B., Antozzi L., et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect. 2005 ; 11 (11). 908-913.
139. Asmundsdottir LR, Erlendsdottir H., Haraldsson G., Guo H., Xu J., Gottfredsson M. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis. 2008 ; 47 (2). e17 - e24.
140. Finkelstein R., Reinhertz G., Hashman N., Merzbach D. Outbreak of Candida tropicalis fungemia in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 1993 ; 14 (10). 587-590.
141. Sherertz RJ, Gledhill KS, Hampton KD, et al. Outbreak of Candida bloodstream infections associated with retrograde medication administration in a neonatal intensive care unit. J Pediatr. 1992 ; 120 (3). 455-461.
142. Huang YC, Lin TY, Leu HS, Peng HL, Wu JH, Chang HY Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection. 1999 ; 27 (2). 97-102.
143. Huang YC, Lin TY, Peng HL, Wu JH, Chang HY, Leu HS Outbreak of Candida albicans fungaemia in a neonatal intensive care unit. Scand J Infect Dis. 1998 ; 30 (2). 137-142.
144. Burnie JP, Odds FC, Lee W., Webster C., Williams JD Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J (Clin Res Ed). 1985 ; 290 (6470). 746-748.
145. Welbel SF, McNeil MM, Kuykendall RJ, et al. Candida parapsilosis bloodstream infections in neonatal intensive care unit patients: epidemiologic and laboratory confirmation of a common source outbreak. Pediatr Infect Dis J. 1996 ; 15 (11). 998-1002.
146. Lasheras A., Rogues AM, Peyrere S., et al. Candida albicans outbreak in a neurosurgical intensive care unit. J Hosp Infect. 2007 ; 65 (2). 181-182.
147. van Asbeck EC, Huang YC, Markham AN, Clemons KV, Stevens DA Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia. 2007 ; 164 (6). 287-293.
148. Chowdhary A., Becker K., Fegeler W., et al. An outbreak of candidemia due to Candida tropicalis in a neonatal intensive care unit. Mycoses. 2003 ; 46 (8). 287-292.
149. McNeil MM, Lasker BA, Lott TJ, Jarvis WR Postsurgical Candida albicans infections associated with an extrinsically contaminated intravenous anesthetic agent. J Clin Microbiol. 1999 ; 37 (5). 1398-1403.
150. Daily MJ, Dickey JB, Packo KH Endogenous Candida endophthalmitis after intravenous anesthesia with propofol. Arch Ophthalmol. 1991 ; 109 (8). 1081-1084.
151. Postsurgical infections associated with an extrinsically contaminated intravenous anesthetic agent-California, Illinois, Maine, and Michigan, 1990. MMWR Morb Mortal Wkly Rep. 1990 ; 39 (25). 426-427 ; 433.
152. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med. 1995 ; 333 (3). 147-154.
153. Solomon SL, Alexander H., Eley JW, et al. Nosocomial fungemia in neonates associated with intravascular pressure-monitoring devices. Pediatr Infect Dis. 1986 ; 5 (6). 680-685.
154. Weems JJ Jr, Chamberland ME, Ward J., Willy M., Padhye AA, Solomon SL Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol. 1987 ; 25 (6). 1029-1032.
155. Beck-Sague CM, Jarvis WR Epidemic bloodstream infections associated with pressure transducers: a persistent problem. Infect Control Hosp Epidemiol. 1989 ; 10 (2). 54-59.
156. Arendrup MC, Fuursted K., Gahrn-Hansen B., et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect. 2008 ; 14 (5). 487-494.
157. Dimopoulos G., Ntziora F., Rachiotis G., Armaganidis A., Falagas ME Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008 ; 106 (2). 523-529 ; table of contents.
158. Bassetti M., Righi E., Costa A., et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006 ; 6: 21.
159. Guery BP, Arendrup MC, Auzinger G., et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 2009 ; 35 (1). 55-62.
160. Lin MY, Carmeli Y., Zumsteg J., et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother. 2005 ; 49 (11). 4555-4560.
161. Chow JK, Golan Y., Ruthazer R., et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008 ; 46 (8). 1206-1213.
162. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149(10):2349-2353.
163. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis. 1995;20(6):1531-1534.
164. Saiman L., Ludington E., Pfaller M., et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J. 2000 ; 19 (4). 319-324.
165. Pfaller MA, Diekema DJ Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007 ; 20 (1). 133-163.
166. Ekenna O, Sherertz RJ, Bingham H. Natural history of bloodstream infections in a burn patient population: the importance of candidemia. Am J Infect Control. 1993;21(4):189-195
167. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640-3645.
168. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17(2):103-109
169. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm
170. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr. 2005;147(2):172-179
171. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002;28(12):1708-1717.
172. Shorr AF, Chung K., Jackson WL, Waterman PE, Kollef MH Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005 ; 33 (9). 1928-1935 ; quiz 1936.
173. Schuster MG, Edwards JE, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008 ; 149 (2). 83-90.
174. Ostrosky-Zeichner L., Sable C., Sobel J., et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007 ; 26 (4). 271-276.
175. Leon C., Ruiz-Santana S., Saavedra P., et al. A bedside scoring system (ĝ€ĝ€ Candida score'') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006 ; 34 (3). 730-737.
176. ClinicalTrials.gov. A randomized, double-blind, placebo controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. US National Institutes of Health. January 16, 2009. Accessed January 19, 2009.
177. Pittet D., Monod M., Suter PM, Frenk E., Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994 ; 220 (6). 751-758.
178. Playford EG, Lipman J., Kabir M., et al. M-1485 Assessment of risk predictive models for invasive candidiasis among a multicentre cohort of Australian ICU patients. Paper presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28, 2008 ; Washington, DC.
179. Alam FF, Mustafa AS, Khan ZU Comparative evaluation of (1, 3)-beta-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis. 2007 ; 7: 103.
180. McMullan R., Metwally L., Coyle PV, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis. 2008 ; 46 (6). 890-896.
181. Ostrosky-Zeichner L., Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005 ; 41 (5). 654-659.
182. Kanda H., Kubo K., Hamasaki K., et al. Influence of various hemodialysis membranes on the plasma (1->3)-beta-D-glucan level. Kidney Int. 2001 ; 60 (1). 319-323.
183. Kimura Y., Nakao A., Tamura H., Tanaka S., Takagi H. Clinical and experimental studies of the limulus test after digestive surgery. Surg Today. 1995 ; 25 (9). 790-794.
184. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR Reactivity of (1->3)-beta-D-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother. 2006 ; 50 (10). 3450-3453.
185. Husain S., Alexander BD, Munoz P., et al. Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003 ; 37 (2). 221-229.
186. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909-917
187. Horner WE, Helbling A, Salvaggio JE, Lehrer SB. Fungal allergens. Clin Microbiol Rev. 1995;8(2):161-179.
188. Berenguer J., Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone- induced immunosuppression. Am J Respir Crit Care Med. 1995 ; 152 (3). 1079-1086.
189. Cornillet A., Camus C., Nimubona S., et al. Comparison of epidemiological, clinical, biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006 ; 43 (5). 577-584.
190. Vandewoude KH, Blot SI, Depuydt P., et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006 ; 10 (1). R31.
191. Bulpa PA, Dive AM, Garrino MG, et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care ? Intensive Care Med. 2001 ; 27 (1). 59-67.
192. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH Immunoparalysis as a cause for invasive aspergillosis ? Intensive Care Med. 2003 ; 29 (11). 2068-2071.
193. Pittet D., Huguenin T., Dharan S., et al. Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 ; 154 (2 pt 1). 541-544.
194. Ader F., Nseir S., Le Berre R., et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect. 2005 ; 11 (6). 427-429.
195. Dimopoulos G., Piagnerelli M., Berre J., Eddafali B., Salmon I., Vincent JL Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother. 2003 ; 15 (1). 71-75.
196. Vieira DF, Van Saene HK, Miranda DR Invasive pulmonary aspergillosis after near-drowning. Intensive Care Med. 1984 ; 10 (4). 203-204.
197. Prodanovic H., Cracco C., Massard J., et al. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol. 2007 ; 7: 2.
198. Trof RJ, Beishuizen A., Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med. 2007 ; 33 (10). 1694-1703.
199. Leroy P., Smismans A., Seute T. Invasive pulmonary and central nervous system aspergillosis after near-drowning of a child: case report and review of the literature. Pediatrics. 2006 ; 118 (2). e509 - e513.
200. Sessa A., Meroni M., Battini G., et al. Nosocomial outbreak of Aspergillus fumigatus infection among patients in a renal unit ? Nephrol Dial Transplant. 1996 ; 11 (7). 1322-1324.
201. Khasawneh F., Mohamad T., Moughrabieh MK, Lai Z., Ager J., Soubani AO Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care. 2006 ; 21 (4). 322-327.
202. Meersseman W., Lagrou K., Maertens J., Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007 ; 45 (2). 205-216.
203. Meersseman W., Lagrou K., Maertens J., et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008 ; 177 (1). 27-34.
204. Cornely OA, Maertens J., Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2 5 2007 ; 356 (4). 348-359.
205. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 ; 356 (4). 335-347.
206. Borro JM, Sole A., de la Torre M., et al. Efficiency and safety of inhaled amphotericin B lipid complex (abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. 2008 ; 40 (9). 3090-3093.
207. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005 ; 41 (5). 634-653.
208. Gonzalez CE, Rinaldi MG, Sugar AM Zygomycosis. Infect Dis Clin North Am. 2002 ; 16 (4). 895-914, vi.
209. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004 ; 17 (6). 517-525.
210. Chakrabarti A., Das A., Mandal J., et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006 ; 44 (4). 335-342.
211. Chayakulkeeree M., Ghannoum MA, Perfect JR Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006 ; 25 (4). 215-229.
212. Zaoutis TE, Roilides E., Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007 ; 26 (8). 723-727.
213. Mitchell SJ, Gray J., Morgan ME, Hocking MD, Durbin GM Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet. 1996 ; 348 (9025). 441-443.
214. Maravi-Poma E., Rodriguez-Tudela JL, de Jalon JG, et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med. 2004 ; 30 (4). 724-728.
215. Reed C., Ibrahim A., Edwards JE Jr, Walot I., Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006 ; 50 (11). 3968-3969.